全文获取类型
收费全文 | 28121篇 |
免费 | 2806篇 |
国内免费 | 927篇 |
专业分类
耳鼻咽喉 | 215篇 |
儿科学 | 601篇 |
妇产科学 | 455篇 |
基础医学 | 4122篇 |
口腔科学 | 753篇 |
临床医学 | 1951篇 |
内科学 | 5964篇 |
皮肤病学 | 551篇 |
神经病学 | 1908篇 |
特种医学 | 481篇 |
外国民族医学 | 5篇 |
外科学 | 2747篇 |
综合类 | 3609篇 |
现状与发展 | 5篇 |
一般理论 | 2篇 |
预防医学 | 1472篇 |
眼科学 | 379篇 |
药学 | 3422篇 |
2篇 | |
中国医学 | 847篇 |
肿瘤学 | 2363篇 |
出版年
2024年 | 46篇 |
2023年 | 566篇 |
2022年 | 816篇 |
2021年 | 1284篇 |
2020年 | 1089篇 |
2019年 | 1386篇 |
2018年 | 1307篇 |
2017年 | 1201篇 |
2016年 | 1074篇 |
2015年 | 1244篇 |
2014年 | 1874篇 |
2013年 | 1843篇 |
2012年 | 1755篇 |
2011年 | 2014篇 |
2010年 | 1775篇 |
2009年 | 1533篇 |
2008年 | 1557篇 |
2007年 | 1406篇 |
2006年 | 1122篇 |
2005年 | 1069篇 |
2004年 | 939篇 |
2003年 | 712篇 |
2002年 | 532篇 |
2001年 | 392篇 |
2000年 | 421篇 |
1999年 | 337篇 |
1998年 | 252篇 |
1997年 | 198篇 |
1996年 | 192篇 |
1995年 | 142篇 |
1994年 | 108篇 |
1993年 | 108篇 |
1992年 | 90篇 |
1991年 | 82篇 |
1990年 | 69篇 |
1989年 | 58篇 |
1988年 | 51篇 |
1987年 | 50篇 |
1985年 | 128篇 |
1984年 | 132篇 |
1983年 | 115篇 |
1982年 | 123篇 |
1981年 | 110篇 |
1980年 | 93篇 |
1979年 | 112篇 |
1978年 | 68篇 |
1977年 | 57篇 |
1976年 | 44篇 |
1975年 | 40篇 |
1973年 | 37篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
The Clinical and Prognostic Implications of Pluripotent Stem Cell Markers Expression and Their Correlation with the WNT signal pathway in Hepatocellular Carcinoma 下载免费PDF全文
Nisreen A.A. OsmanAlzahraa Ibrahim KhalilRehab Kamal Yousef 《Asian Pacific journal of cancer prevention》2020,21(10):2961-2970
Objectives: This study aimed to investigate the expression of SOX2, SOX9, p53, and β-catenin in hepatocellular carcinoma (HCC) and their correlation with clinicopathological parameters of prognostic importance. Materials and Methods: Seventy-five patients were enrolled in this study. All patients had full clinical and follow-up data and available paraffin blocks. Immunohistochemical analysis was performed and correlated with clinicopathological factors and patient survival. Results: We detected the positive expression of SOX2, SOX9, p53, and β-catenin in 76%, 50.7%, 50.7%, and 77.9% of HCC specimens respectively. All studied markers showed a significant increase in the expression in tumor tissue specimens compared to non-tumor tissue. Both SOX2 and SOX9 expressions were significantly associated with adverse prognostic factors in HCC. Significant positive correlations were found between SOX2 and SOX9 and both p53 and β-catenin expression (r= 0.528, 0.485 and; r = 0.253, 0.327, respectively; p < 0.0001 for both of them). Regarding survival, we found that HCC patients with positive SOX2 and SOX9 expressions had significantly shorter overall survival (p=0.0001, each). Additionally, larger tumor size, tumor grade, high stage, tumor multiplicity, presence of cirrhosis, tumor necrosis, high p53 expression, and positive β-catenin expression were independent predictors of worse survival. A multivariate Cox analysis revealed that tumor grade, stage, p53, and SOX2 expression were independent predictors of unfavorable prognosis in overall survival (p=0.0001, p=0.0001,p=0.033; and p=0.003, respectively). Conclusions: Our findings might provide an insight into SOX2 and SOX9’s role in HCC and suggest that SOX2 might be targeted for HCC therapy. 相似文献
32.
《Drug metabolism and pharmacokinetics》2019,34(1):87-94
The purpose of this study was to elucidate the involvement of Mate1 in the tubular secretion of trimethoprim and saturation of Mate1-mediated efflux to address the mechanisms underlying the pharmacokinetic drug interactions with trimethoprim. Trimethoprim is a more potent inhibitor of MATE2-K than MATE1 with Ki values (μM) of 0.030–0.28 and 2.4–5.9, respectively. Trimethoprim is a substrate of human MATE1 and MATE2-K with Km values of 2.3 ± 0.9 and 0.018 ± 0.004 μM, and mouse Mate1, but not human OCT2, mouse Oct1 and Oct2. Pyrimethamine significantly reduced the renal clearance (CLR) of trimethoprim (mL/min/kg) from 40.0 ± 5.1 to 20.1 ± 3.7 (p < 0.05). Trimethoprim was given to mice at three infusion rates (150, 500, and 1500 nmol/min/kg). Together with an increase in the plasma concentrations of trimethoprim, the CLR (mL/min/kg) of trimethoprim decreased to 25.9 ± 3.2, 13.5 ± 5.7, and 8.92 ± 1.50 at the respective rates. Trimethoprim decreased the CLR of rhodamine 123 in an infusion rate-dependent manner: 11.5 ± 1.3 (control), 5.17 ± 1.55, 1.31 ± 0.50, and 0.532 ± 0.180. These results suggest that Mate1 mediates the tubular secretion of trimethoprim, and at therapeutic doses, MATEs-mediated efflux can be saturated, and thereby, cause drug interactions with other MATE substrates. 相似文献
33.
SEPT9是13个Septin同源基因家族之一,参与调控众多过程,包括细胞分裂、细胞极化、细胞迁移以及线粒体分裂等。研究表明在众多肿瘤中,SEPT9都发挥着作用,尤其在结直肠肿瘤研究领域,外周血SEPT9基因甲基化检测更是研究热点,其检测的敏感度和特异度相对于其他糖蛋白肿瘤标志物、粪便隐血试验和粪便免疫化学测试等更具有优势,相对于结直肠镜等侵入性检查更节约成本,同时有着更好的依从性。本文对SEPT9的功能、与结直肠癌之间的关系以及对结直肠肿瘤的筛查及诊断价值做一综述。 相似文献
34.
35.
36.
目的总结应用踇甲皮瓣再造拇指及腓动脉穿支皮瓣游离移植修复足部供区的手术方法及临床效果。方法2016 年 6 月—2018 年 5 月,应用踇甲皮瓣联合腓动脉穿支皮瓣游离移植再造拇指并修复足部供区 15 例。男 10 例,女 5 例;年龄 21~48 岁,平均 34.6 岁。致伤原因:重物压砸伤 7 例,机器绞伤 5 例,电锯切割伤 3 例。Ⅰ度缺损 9 例,Ⅱ度缺损 6 例。入院至皮瓣手术时间 4~7 d,平均 5.2 d。结果术后踇甲皮瓣及腓动脉穿支皮瓣全部成活,切口均Ⅰ期愈合。患者均获随访,随访时间 8~24 个月,平均 16.4 个月。末次随访时,再造拇指指甲生长平整,有光泽,指腹饱满;足部皮瓣外形良好,颜色及质地接近受区。根据中华医学会手外科学会拇手指再造功能评定标准,获优 9 例、良 6 例;根据 Maryland 足功能评分标准,获优 10 例、良 5 例。患者行走步态正常,无跛行及疼痛不适。结论踇甲皮瓣修复拇指Ⅰ、Ⅱ度缺损,再造拇指可获得良好外观及功能;腓动脉穿支皮瓣具有血供可靠、血管恒定、易切取等优点,可有效修复足部供区。 相似文献
37.
《Sleep medicine》2020
BackgroundThe peripheral level of matrix metalloproteinase (MMP)-9 and polymorphism of MMP9 -1562C>T in patients with obstructive sleep apnea (OSA) remains controversial. Therefore, the aims of this systemic review and meta-analysis are to assess the MMP9 level in OSA patients and identify the relationship between MMP9 -1562C>T and OSA susceptibility.MethodsThis systematic review was performed following the PRISMA guideline. We searched for studies in major databases, identifying those indexed from inception to July 3, 2019 which related to MMP9 level, MMP9 -1562C>T and OSA. The pooled standardized mean differences (SMDs) and 95% confidence interval (CI) of MMP9 levels were calculated. In addition, the relationship between MMP9 -1562C>T and OSA susceptibility was assessed by three genetic models. The heterogeneity analysis and calculation of the pooled odds ratio (OR) were also performed, followed by quality assessment using the Newcastle-Ottawa Scale (NOS).ResultsIn sum, our review included 15 eligible studies regarding MMP9 level and three regarding MMP9 -1562C>T. The pooled results showed that peripheral level of MMP9 was increased in OSA patients (SMD = 1.37; 95% CI = 1.15–1.59). Furthermore, significant difference of MMP9 level can be found between severe and mild-to-moderate OSA patients (SMD = 28.17; 95% CI = 4.23–52.11) or between moderate-severe and mild OSA (SMD = 36.62; 95% CI = 12.19–61.04). However, no relationship was observed between MMP9 -1562C>T and OSA susceptibility in three genetic models (Homozygote model, OR = 1.37; 95% CI = 0.87–2.18); (Recessive model, OR = 1.42; 95% CI = 0.83–2.42); (Allele model, OR = 1.07; 95% CI = 0.96–1.18).ConclusionsThis systemic review and meta-analysis indicated that the level of MMP9 was increased in patients with OSA and this increase is relevant to OSA severity. Moreover, the relationship between MMP9 -1562 C>T and OSA susceptibility has currently not been proven by current merging values. Further analyses with larger sample size are required to verify these associations. 相似文献
38.
39.
40.
驱动基因的发现及针对驱动基因的靶向治疗已显著提高了肺癌患者的生存质量和时间,但目前对于BRAF、HER2、MET、RET等少见驱动基因改变肺癌患者的靶向药物的选择仍然较少。近年来免疫检查点抑制剂在肺癌治疗中取得了一定的疗效,但因为少见驱动基因突变的肺癌患者本身样本量少,开展大规模临床随机对照试验尚存在一定的困难,目前此类患者接受免疫检查点抑制剂治疗的疗效情况仍不明确。本文将对目前已掌握的免疫检查点抑制剂治疗BRAF、HER2、MET、RET等少见驱动基因改变肺癌患者的临床研究结果进行综述,以期在一定程度上为临床工作提供一些依据和参考。 相似文献